Attovia (ATTO) CFO Receives 140,000-Share Award

What Happened Attovia Therapeutics’ Chief Financial Officer received a grant/award for 140,000 derivative shares on August 4, 2026. The filing reports an acquisition price of $0.00 per share and a total reported acquisition value of $0 — this is an equity award (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-04; Filing date (Form 4): 2026-08-06 (filed within the typical 2-business-day window).
• Shares/units granted: 140,000 (reported as a derivative award at $0.00 per share).
• Shares owned after transaction: Not disclosed in this filing.
• Vesting (footnote): 25% of the options shall vest on August 4, 2027; the remaining options vest in equal monthly installments over the following 36 months, subject to continued service.
• No indication of sale, purchase, tax-withholding, or 10b5-1 plan in this report.

Context This transaction is a compensation-related equity award for the CFO. Such grants vest over time and do not represent an immediate market buy or sell — they reflect future potential ownership if vesting conditions are met. Retail investors should view this as executive compensation rather than a direct trading signal.